#81 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need accessible tools to screen for cannabis-drug interactions because cannabis inhibits cytochrome P450 enzymes and can significantly alter the metabolism of commonly prescribed medications like warfarin, SSRIs, and benzodiazepines. Free interaction-checking resources enable providers to counsel patients on potential risks without requiring specialized knowledge, reducing adverse events and improving medication safety in an era of increasing cannabis use. This is particularly critical given that many patients use cannabis without disclosing it to their healthcare providers, leaving clinicians unaware of dangerous polypharmacy combinations.
Cannabis has the potential to interact with numerous commonly prescribed medications including anticoagulants, antidepressants, and sedatives, which can alter drug metabolism and clinical efficacy. The Green Bridge Society offers clinicians and patients a free tool to screen for potential cannabis-drug interactions, addressing a critical gap in clinical practice where many providers lack readily accessible resources to assess compatibility between cannabis use and concurrent medications. Given that cannabis use is increasingly prevalent among patients with chronic conditions who are already on multiple medications, understanding these interactions is essential for optimizing therapeutic outcomes and minimizing adverse effects. The cytochrome P450 enzyme system represents a major mechanism through which cannabis can inhibit or induce metabolism of numerous drugs, potentially leading to subtherapeutic or toxic drug levels. Clinicians should routinely screen patients for cannabis use and utilize interaction-checking tools to identify potential risks before recommending cannabis or when patients report concurrent use with their existing medication regimens. Having access to free, evidence-based interaction resources enables providers to have informed conversations with patients about the safety profile of cannabis in their specific clinical context.
“What we’re seeing in clinical practice is that patients often don’t disclose their cannabis use to their physicians, and physicians don’t routinely ask, which means we’re missing significant drug interactions with medications like warfarin, SSRIs, and benzodiazepines that could affect efficacy or safety. Tools like interaction checkers are useful, but the real work happens in the clinical encounter when we create a non-judgmental space to discuss cannabis as we would any other substance our patients are taking.”
🔍 Clinicians should be aware that cannabis can inhibit or induce hepatic cytochrome P450 enzymes, potentially altering the metabolism of numerous commonly prescribed medications including warfarin, selective serotonin reuptake inhibitors, and benzodiazepines. While interaction databases and screening tools like those offered by Green Bridge Society can raise awareness, evidence on the clinical significance of most cannabis-drug interactions remains sparse, and interaction severity depends on multiple variables including cannabis dose, cannabinoid profile, individual metabolic factors, and duration of use. Given the increasing prevalence of cannabis use among patients—many of whom may not disclose it without direct questioning—routinely asking about cannabis consumption during medication reconciliation is important, particularly when prescribing narrow-therapeutic-index drugs or when patients report unexpected medication efficacy changes. However, clinicians should recognize that conclusive guidance on specific interaction management is limited by the lack of rigorous
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
